HLNE Stock Analysis: Hamilton Lane | NASDAQ
Asset Management | NASDAQ, USA | Market Cap: 7.027m USD | 12M Return: -32% | US4074971064 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 69.5M
EPS Trend: 95.4%
Qual. Beats: 1
Rev. Trend: 92.6%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 9.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Hamilton Lane Incorporated (NASDAQ: HLNE) is a Philadelphia-based private markets investment firm founded in 1991 that specializes in private equity and venture capital across the full company lifecycle, from early venture and emerging growth to buyouts, distressed, and mezzanine investments. The firm operates multiple alternative investment strategies, including direct credit, direct investments, fund of funds (primary and secondary), evergreen funds, and real assets, typically committing between $0.25 million and $100 million per company and favoring majority stakes in small- to mid-sized enterprises. Its investment focus spans a broad range of sectors such as technology, healthcare, energy, industrials, financials, and consumer services, with a preference for disruptive and innovative businesses, and it invests globally across North America, Europe, Asia/Pacific, Latin America, the Middle East, and Africa. Listed since its 2017 IPO and classified within the Financials sector (Asset Management & Custody Banks), Hamilton Lane supports institutional and private wealth clients with private markets exposure, supplementing its direct deal activity with comprehensive fund-of-funds and advisory capabilities.
- Evergreen and private wealth AUM growth drives fee earnings expansion
- Carried interest realizations depend on private market exit activity
- Fee compression and rate exposure pressure private markets margins
| Net Income: 275.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA -4.22 > 1.0 |
| NWC/Revenue: 51.24% < 20% (prev 27.81%; Δ 23.43% < -1%) |
| CFO/TA 0.16 > 3% & CFO 399.0m > Net Income 275.9m |
| Net Debt (118.4m) to EBITDA (541.9m): 0.22 < 3 |
| Current Ratio: 4.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (54.4m) vs 12m ago -0.10% < -2% |
| Gross Margin: 79.30% > 18% (prev 71.00%; Δ 8.30% > 0.5%) |
| Asset Turnover: 39.55% > 50% (prev 38.41%; Δ 1.14% > 0%) |
| Interest Coverage Ratio: 36.46 > 6 (EBIT TTM 532.0m / Interest Expense TTM 14.6m) |
| A: 0.17 (Total Current Assets 584.1m - Total Current Liabilities 144.3m) / Total Assets 2.54b |
| B: 0.26 (Retained Earnings 670.5m / Total Assets 2.54b) |
| C: 0.25 (EBIT TTM 532.0m / Avg Total Assets 2.17b) |
| D: 1.11 (Book Value of Equity 939.3m / Total Liabilities 846.6m) |
| Altman-Z'' = 4.81 = AA |
| DSRI: 1.03 (Receivables 228.0m/178.2m, Revenue 858.4m/692.2m) |
| GMI: 0.90 (GM 71.00% / 79.30%) |
| AQI: 1.10 (AQ_t 0.73 / AQ_t-1 0.66) |
| SGI: 1.24 (Revenue 858.4m / 692.2m) |
| TATA: -0.05 (NI 275.9m - CFO 399.0m) / TA 2.54b) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of August 14, 2026, the stock is trading at USD 107.19 with a total of 559,482 shares traded. Over the past week, the price has changed by +8.89%, over one month by +32.24%, over three months by +24.49% and over the past year by -32.00%.
Current recommended Stop Loss: 100.00 (which is 6.7% or 1.8 ATR below the current price).
Hamilton Lane has received a consensus analysts rating of 2.83. Therefore, it is recommended to hold HLNE.
- StrongBuy: 0
- Buy: 0
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 133.6 | 24.6% |
P/E Trailing = 15.9574
P/E Forward = 14.0845
P/S = 8.1769
P/B = 5.8884
P/EG = 1.39
Revenue TTM = 858.4m USD
EBIT TTM = 532.0m USD
EBITDA TTM = 541.9m USD
Long Term Debt = 274.2m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 455.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 90.6m
Net Debt = 118.4m USD (calculated: Debt 455.4m - CCE 337.0m)
Enterprise Value = 7.14b USD (7.03b + Debt 455.4m - CCE 337.0m)
Interest Coverage Ratio = 36.46 (Ebit TTM 532.0m / Interest Expense TTM 14.6m)
EV/FCF = 19.36x (Enterprise Value 7.14b / FCF TTM 369.1m)
FCF Yield = 5.17% (FCF TTM 369.1m / Enterprise Value 7.14b)
FCF Margin = 43.00% (FCF TTM 369.1m / Revenue TTM 858.4m)
Net Margin = 32.14% (Net Income TTM 275.9m / Revenue TTM 858.4m)
Gross Margin = 79.30% ((Revenue TTM 858.4m - Cost of Revenue TTM 177.6m) / Revenue TTM)
Gross Margin QoQ = none% (prev 69.78%)
Tobins Q-Ratio = 2.81 (Enterprise Value 7.14b / Total Assets 2.54b)
Interest Expense / Debt = 3.20% (Interest Expense 14.6m / Debt 455.4m)
Taxrate = 15.83% (81.9m / 517.4m)
NOPAT = 447.8m (EBIT 532.0m * (1 - 15.83%))
Current Ratio = 4.05 (Total Current Assets 584.1m / Total Current Liabilities 144.3m)
Debt / Equity = 0.48 (Debt 455.4m / totalStockholderEquity, last quarter 939.3m)
Debt / EBITDA = 0.22 (Net Debt 118.4m / EBITDA 541.9m)
Debt / FCF = 0.32 (Net Debt 118.4m / FCF TTM 369.1m)
Total Stockholder Equity = 889.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.71% (Net Income 275.9m / Total Assets 2.54b)
RoE = 31.02% (Net Income TTM 275.9m / Total Stockholder Equity 889.4m)
RoCE = 45.72% (EBIT 532.0m / Capital Employed (Equity 889.4m + L.T.Debt 274.2m))
RoIC = 19.04% (NOPAT 447.8m / Invested Capital 2.35b)
WACC = 10.62% (E(7.03b)/V(7.48b) * Re(11.13%) + D(455.4m)/V(7.48b) * Rd(3.20%) * (1-Tc(0.16)))
Discount Rate = 11.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 7.55 | Cagr: -0.03%
[DCF] Terminal Value 69.29% ; FCFF base≈356.7m ; Y1≈385.4m ; Y5≈472.7m
[DCF] Fair Price = 117.3 (EV 5.20b - Net Debt 118.4m = Equity 5.08b / Shares 43.3m; r=10.62% [WACC]; 5y FCF grow 9.20% → 2.50% )
EPS Correlation: 95.38 | EPS CAGR: 24.85% | SUE: 2.54 | # QB: 1
Revenue Correlation: 92.58 | Revenue CAGR: 12.72% | SUE: 2.83 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.75 | Chg30d=+17.00% | Revisions=-50% | Analysts=5
EPS next Quarter (2026-12-31): EPS=1.73 | Chg30d=+13.32% | Revisions=-50% | Analysts=5
EPS current Year (2027-03-31): EPS=7.60 | Chg30d=+24.12% | Revisions=+62% | GrowthEPS=+28.9% | GrowthRev=+31.9%
EPS next Year (2028-03-31): EPS=7.38 | Chg30d=+0.11% | Revisions=-29% | GrowthEPS=-2.9% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: -17% (up=6, down=9)